Sort by
Refine Your Search
-
Category
-
Employer
-
Field
-
having accurate and well-informed reconstructions of the ecologies of ancient animals. This is key to our understanding of the broad-scale development of life on Earth and global ecosystems. Arthropods
-
-linguistic dimensions of development, and the extent to which study-abroad experiences transfer to participants' subsequent academic, professional, and personal lives. LINC will collect and analyse a rich
-
: April 1, 2027) is intended to contribute to living expenses during the elaboration phase of a dissertation project in literary studies. The aim of the start-up grant is to prepare and submit a competitive
-
, imaging or diagnosis. This PhD project will develop stimuli-responsive nanozyme coatings for personalized medical implants. Nanozymes are nanomaterials capable of mimicking the catalytic activity of natural
-
graduate during the starting phase of his/her PhD research project. It is expected that he/she will develop a funding proposal during the first six months for applying to the Swiss National Science
-
, including buildings, sports, and occupational safety. The project will establish the scientific and methodological foundation for the development and validation of innovative strategies to protect people from
-
to novel personalized strategies of particles de-sign for drug delivery, imaging or diagnosis. This PhD project will develop stimuli-responsive nanozyme coatings for personalized medical implants. Nanozymes
-
description Develop skills in atmospheric chemistry, global modeling, and data analysis of field observations. Have opportunities to develop scientific communication skills through presentations at conferences
-
internationally in our research and study programs. The PhD candidate will join the Human Development group at the Faculty of Psychology, University of Basel and contribute to a research program investigating the
-
), is internationally recognized for its pioneering research in radiopharmaceutical chemistry, and targeted radionuclide therapy. The research group of Prof. Roger Schibli develops innovative